Aptevo targets IND-enabling studies for trispecific cancer drug APVO451 in 1H 2027
APVO•Aptevo is preparing its lead trispecific oncology candidate APVO451 for IND-enabling studies targeted for the first half of 2027, while focusing on manufacturing optimization.
1. Manufacturing focus
Aptevo is focusing on reliable, scalable production of its next-generation trispecific oncology programs as it prepares APVO451 for IND-enabling studies targeted for the first half of 2027. The company says manufacturing progress could validate its ADAPTIR-FLEX platform and support additional candidates and potential partnering options.
